Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/129547NUCLEIC ACID VACCINES
WO 23.06.2022
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/EP2021/086528 Applicant UNIVERSITY OF COPENHAGEN Inventor BERTELSEN, Adam Frederik Sander
The present invention relates to modular nanoparticle-based compositions based on nucleic acids, such as DNA and RNA, which are particularly useful in prophylaxis and/or treatment of diseases and disorders.
2.WO/2022/130342TETRAVALENT FZD AND WNT CO-RECEPTOR BINDING ANTIBODY MOLECULES AND USES THEREOF
WO 23.06.2022
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
Appl.No PCT/IB2021/061972 Applicant ANTLERA THERAPEUTICS INC. Inventor ANGERS, Stephane
Described herein are tetravalent binding antibody molecules comprising a FZD receptor binding domain and an LRP5/6 co-receptor binding domain on opposite termini of an Fc domain that activate a Wnt beta-catenin signaling pathway and methods for their use.
3.WO/2022/132202COMBINATION THERAPY FOR THE TREATMENT OF CANCER
WO 23.06.2022
Int.Class C07K 14/495
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
475Growth factors; Growth regulators
495Transforming growth factor (TGF)
Appl.No PCT/US2021/010067 Applicant BICARA THERAPEUTICS INC. Inventor MARIGOWDA, Shivakumar, Bhadravathi
Provided herein are methods of treating cancer by administering to a subject having cancer an antibody, or functional fragment or functional variant thereof, that specifically binds programmed cell death protein 1 (PD1); and a fusion protein that comprises a targeting moiety and an immunomodulatory moiety, wherein: i) said targeting moiety specifically binds epidermal growth factor receptor (EGFR); and (ii) said immunomodulatory moiety comprises an amino acid sequence of the extracellular domain of transforming growth factor-beta receptor Il (TGFβRII).
4.WO/2022/127372CAR-INKT WITH HIGH AMPLIFICATION, SURVIVAL CAPACITY AND TUMOR KILLING EFFECT AND USE THEREOF
WO 23.06.2022
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No PCT/CN2021/125615 Applicant BEIJING GENE KEY LIFE TECHNOLOGY CO., LTD. Inventor LYU, Jun
Provided in the present application is a chimeric antigen receptor, including a GPC3 antigen binding domain, an ICD1, ICD2 or ICD3 intracellular signal stimulation domain with amino acid sequences of SEQ ID NOs: 29, 31 and 33, respectively, and an IL-15-IL-15α fusion protein with an amino acid sequence of SEQ ID NO:7. After the chimeric antigen receptor is transferred into immune cells, especially iNKT cells, the cell proliferation rate, survival time and tumor killing effect can be effectively improved. Further provided in the present application are a corresponding expression vector, a transduction system, a pharmaceutical use, independent ICD1, ICD2 and ICD3 intracellular signal stimulation domains, and an IL-15-IL-15α fusion protein.
5.WO/2022/130432NUCLEOTIDE SEQUENCE EXPRESSING AN EXTRACELLULAR VESICLE-ANCHORING PROTEIN FUSED WITH SARS-COV-2 ANTIGENS AND RELATED FUSION PROTEIN FOR USE AS VACCINE
WO 23.06.2022
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/IT2021/050405 Applicant ISTITUTO SUPERIORE DI SANITA' Inventor FEDERICO, Maurizio Paolo Maria
The present invention concerns a nucleotide sequence expressing an extracellular vesicle-anchoring protein fused with SARS-CoV-2 antigens and related fusion protein for use as vaccine, wherein said extracellular vesicle-anchoring protein is Nefmut or a truncated form of Nefmut.
6.WO/2022/129937IMMUNOGENIC PEPTIDE
WO 23.06.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/GB2021/053351 Applicant UCL BUSINESS LTD Inventor REEVES, Matthew Bryan
P120670PCT 56 ABSTRACT Immunogenic peptide The invention provides a human herpesvirus immunogenic peptide comprising a novel antigenic domain (AD) of glycoprotein B, termed AD-6. The invention also provides a nucleic acid sequence encoding said immunogenic peptide and an inhibitor that binds to said 5 immunogenic peptide. Also provided are an immunogenic composition, a pharmaceutical composition and a vaccine comprising said immunogenic peptide, nucleic acid sequence or inhibitor, and methods of treating or preventing a human herpesvirus infection.
7.WO/2022/132982METHODS OF MANUFACTURING BIOLOGICAL THERAPIES
WO 23.06.2022
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/US2021/063641 Applicant AMGEN INC. Inventor JOH, Nathan
Methods of manufacturing a biological therapy are described. The methods can comprise detecting a level of a molecular attribute of the biological therapy in a formulation, determining a rate of change of the molecular attribute under the storage conditions, and estimating a level of molecular attribute exposure received by the subjects at the time of said administration. Production lots of the biological therapy comprising the molecular attribute can be manufactured comprising the molecular attribute at or below a specified specification for permissible levels of the molecular attribute based on the estimated level of molecule attribute exposure. Methods of developing a manufacturing process for a biological therapy are described. Methods of assessing the clinical impact of a molecular attribute of a biological therapy are described.
8.WO/2022/133042CEA5 BINDING MOLECULES AND USES THEREOF
WO 23.06.2022
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/US2021/063727 Applicant BIOARDIS, LLC Inventor HAERIZADEH, Farzad
Disclosed herein are carcinoembryonic antigen 5 (CEA5)-specific binding polypeptides. These binding polypeptides may be incorporated into chimeric antigen receptors (CARs). Also disclosed herein are methods of using these binding polypeptides and/or CARs for the treatment of, for example, a cancer.
9.WO/2022/133057TREATMENT OF CANCER WITH NK CELLS AND A CD20 TARGETED ANTIBODY
WO 23.06.2022
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No PCT/US2021/063746 Applicant ARTIVA BIOTHERAPEUTICS, INC. Inventor HWANG, Yu Kyeong
Provided herein are, among other things, methods for treating a patient suffering from a CD20+ cancer
10.WO/2022/133102PI3K INHIBITORS FOR PROTECTION AGAINST GLUCOCORTICOID-INDUCED ATROPHY
WO 23.06.2022
Int.Class A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
Appl.No PCT/US2021/063832 Applicant NORTHWESTERN UNIVERSITY Inventor BUDUNOVA, Irina
Provided herein are methods of treating and preventing steroid-induced atrophy (e.g., skin atrophy, osteoporosis, etc.) by the administration of PI3K/Akt/mTOR inhibitors and pharmaceutical compositions and combinations therefor.